Our central research hypothesis is that targeted reactivation of the p53 pathway could provide a new treatment option for patients with neuroblastoma. We will preclinically evaluate combination therapies with the MDM2 inhibitor RG7388, attempt to start a pediatric phase I clinical trial with RG7388, preclinically examine mutant p53 reactivating compounds, and explore p53-targeting miRNAs as a possible new therapeutic target.